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Abstract
Background: The immigrant population has increased greatly in Spain in recent years to the point
where immigrants made up 12% of the infant population in 2008. There is little information available
on the profile of this group with regard to prescription drug utilization in universal public health
care systems such as that operating in Spain. This work studies the overall and specific differences
in prescription drug utilization between the immigrant and Spanish population.
Methods: Use was made of the Aragonese Health Service databases for 2006. The studied
population comprises 159,908 children aged 0-14 years, 13.6% of whom are foreign nationals.
Different utilization variables were calculated for each group. Prescription-drug consumption is
measured in Defined Daily Doses (DDD) and DDD/1000 persons/day/(DID).
Results: A total of 833,223 prescriptions were studied. Utilization is lower for immigrant children
than in Spanish children for both DID (66.27 v. 113.67) and average annual expense (€21.55 v.
€41.14). Immigrant children consume fewer prescription drugs than Spanish children in all of the
therapy groups, with the most prescribed (in DID) being: respiratory system, anti-infectives for
systemic use, nervous system, sensory organs. Significant differences were observed in relation to
the type of drugs and the geographical background of immigrants.
Conclusion: Prescription drug utilization is much greater in Spanish children than in immigrant
children, particularly with reference to bronchodilators (montelukast and terbutaline) and
attention-disorder hyperactivity drugs such as methylphenidate. There are important differences
regarding drug type and depending on immigrants' geographical backgrounds that suggest there are
social, cultural and access factors underlying these disparities.
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We have witnessed a profound transformation in Spanish
society in recent years resulting from the large increase in
the immigrant population, most of whom have come
from low-income countries [1-4]. Contrary to the situa-
tion a number of decades back, Spain is now considered a
destination country for migratory flow.
According to Spanish National Institute of Statistics data
taken from the Spanish Population Register on 1 January
2008, immigrants make up 12.7% of the total population
of Spain. Immigrants comprise 12.46% of the child (≤14
years of age) population in Spain. In 2008, immigrants in
the region of Aragon, where the study was made,
accounted for 13.14% of the total population and 13.38%
of the paediatric population
Spain is the European Union country that received the
largest number of immigrants in 2007. The number of res-
ident foreign nationals has multiplied by 3 in the last 6
years. It is clear that an increase of this scale in the immi-
grant population in such a short period of time involves
adapting and reorganizing a number of aspects of the host
society. This occurrence requires the destination society to
undertake preparations in many aspects, among which are
the public health service and health care. Awareness of the
habits and needs of this population group is therefore of
great interest so that resources may be planned and the
necessary measures taken in order to for them to be faced
in the best possible conditions [1,4-9].
Health care for non-EU foreign nationals in Spain is regu-
lated by law and is guaranteed for foreign nationals,
regardless of their residency status, in the same conditions
as Spaniards [10]. Therefore, all children with foreign
national status are covered by public health care, which is
the same as that of the Spanish population.
Health care professionals and the public at large are gen-
erally unaware of the health care needs of, and services
provided to, the immigrant population [5,7,11]. How-
ever, immigrants are believed to contribute to greater uti-
lization of health care resources resulting in overcrowded
health centres and accident and emergency services, and
they are believed to have higher utilization of prescription
drugs [12-15].
Despite the increase in recent years in the number of stud-
ies directed at analysing the health of immigrants, these
studies tend to focus on medical aspects such as the prev-
alence of different diseases and conditions among foreign
nationals, care procedures to be applied and mortality
rates, among others [2,3,16-20]. However, there are very
few studies aiming to discover the repercussions of pro-
viding health care to immigrants inside the health service,
with a view to directing health policies and improving
care. These studies additionally do not tend to focus on
the paediatric population [5-7,11,21-25].
Pharmaceutical expense is one of the fastest growing com-
ponents of the Spanish National Health Service budget.
Subsidies for prescriptions dispensed in community phar-
macies account for approximately 25% of total health care
spending [26]. The expenditure generated by the immi-
grant population is therefore an important aspect to study
when analysing the repercussions the immigration phe-
nomenon is having on the public health system, given
that the available information is very scarce. Additionally,
as pharmaceutical expense is the result of prescriptions
made by public health service doctors, this information is
a good indication of the health care delivered.
In 2006, the population of Aragon (an autonomous
region in northeastern Spain), all with access to public
health care, was 1,273,662, of which 116,677 (9.16%)
were foreign nationals. In the same year, 24,400,843 pre-
scriptions were dispensed and billed to the Aragonese
Public Health Service (SALUD) for a total value of
€377,262,671. Public health system subsidies accounted
for €341,731,076 of this amount.
Our study aims to provide insight into one of the least
known aspects of the impact produced by the immigrant
population on the Spanish health system - prescription
drug utilization - compared to the Spanish population.
The objectives of our work were:
1. to study the overall and specific differences in prescrip-
tion drug utilization between the immigrant and Spanish
paediatric population residing in a Spanish region; and 2.
to understand the profile of drugs prescribed to both pop-
ulation groups, with regard to the main therapeutic
groups prescribed and to the active ingredients that gener-
ate the greatest expense.
Methods
This is a descriptive observational study on prescription
drug utilization comparing the two different populations
residing in Aragon: Spaniards and immigrants. In order to
give an operational definition of immigrant, we have used
the legal category of foreign national. This article makes
use of both terms indistinctly [27]. Study population was
the whole paediatric population of Aragon, both Span-
iards and foreign nationals, with access to health care pro-
vided by SALUD accredited by their corresponding
personal health insurance card. The period covered by the
study was 1 January to 31 December 2006. This research
has been aproved by Ethic Committe of Clinic Research of
Aragon.Page 2 of 9
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Pharmacy Service pharmaceutical billing database statis-
tics for 2006 covering all publicly subsidised prescription
drugs dispensed by pharmacies. These do not include
drugs prescribed by private practices or those dispensed
without prescription. Nor do they include drugs utilized
in hospitals or dispensed there to outpatients (very spe-
cific treatments for particular diseases and conditions).
Drugs corresponding to immunization campaigns are
also excluded from this study. The data collected are cross-
sectional. Long-term drug utilization patterns were not
studied.
In order for their bills to be settled by the Pharmacy Serv-
ice, pharmacists must use the computerized data-collec-
tion system to record the details of the prescribed drug
(national drug formulary code), those of the prescribing
doctor (health area identification code and registration
number) and those of the patient for whom the drug is
prescribed (personal identification code), among others.
By matching the personal identification code with the
information from the health insurance card, which pro-
vides information on users' age, sex, country of birth and
status (Spanish or foreign national), data can be obtained
on utilization by age and sex of the local Spanish and
immigrant population.
By matching the drug code with the drug formulary data-
base, Digitalis, information can be obtained regarding the
active ingredient, Anatomical Therapeutic Chemical
(ATC) classification therapeutic main group and sub-
group, the content in DDDs in each package needed to
calculate the DID and whether it is a generic drug [28].
Statistical Analysis: Prescription drug utilization is com-
pared by age, sex and foreign national or Spanish in the
health card database. We applied the central limit theo-
rem for large samples. The DID variable has a normal dis-
tribution and we were therefore able to use Student's t-test
to compare these values between the immigrant and
Spanish populations. P-values < 0.05 were considered sta-
tistically significant.
For each patient: DID, prescriptions, packages, health sys-
tem subsidy, retail price of prescription drugs, utilization
rate (patients utilizing the drug/drugs in 2006 compared
to the total population by age at year's end) and percent-
age of generics utilized compared to total DDD.
Analysis was performed on anatomical groups, therapeu-
tic groups and active ingredients with the purpose of
ascertaining whether the differences in utilization occur in
a similar manner in all prescription drug groups or
whether, on the contrary, there is a different utilization
profile. All of the prescribed and dispensed drugs and
healthcare products were grouped according to the ATC
classification system by anatomical main group, thera-
peutic main group, pharmacological and chemical sub-
groups, and active ingredients.
Inferential data analysis, which attempts to compare
mean utilization per age and sex group, was performed
using Student's t-test for independent samples. In order to
be able to use this parametric contrast, we defined the cen-
tral limit theorem, because this allowed us to work with a
normal distribution when analysing the mean of a varia-
ble and, consequently, with parametric inference. The
DID variable has a normal distribution and we were there-
fore able to use Student's t-test to compare these values
between the immigrant and Spanish populations. P-val-
ues < 0.05 were considered statistically significant.
Results
A total of 833 223 prescriptions made to children between
the ages of 0 and 14 years were analysed. The reference
population was 159 908 children residing in Aragon in
2006 of whom 13.6 (19 231) were foreign nationals. 24%
of these foreign national children were born in Spain. The
distribution by geographical background is as follows:
40% from South and Central America; 32% from Non
EU- Europe; 21% from Africa; 8% of other origin.
Figure 1 shows the differences in DID between children,
with regard to age and sex.
Table 1 provides general information on prescription drug
utilization for Spanish and foreign national children in
Aragon regarding: DID, packages/person, expense/person,
retail price/person, % co-payment - (retail price-expense/
retail price) and utilization rate (percentage of the popu-
lation that utilized at least one prescription in the year).
In all of the measurement units used - DDD, DID, pack-
ages, expense and retail price per person, prescription
drug utilization by the Spanish population is far higher
than that of the immigrant population (between 51% and
100%), with a great degree of significance.
Foreign nationals pay a higher co-payment percentage, no
doubt owing to the lower value of their utilization of
drugs for chronic conditions (with lower co-payment)
than Spaniards. The prescription drug utilization rate for
foreign nationals is only 16% lower than that of Span-
iards, which means that the fundamental difference lies in
the number of drugs consumed per person and the value
of those drugs, rather than the number of children who
utilized them.Page 3 of 9
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foreign nationals in the 18 anatomical and therapeutic
groups studied, together with the general DID data previ-
ously presented.
It can be observed that the differences in utilization are
not homogeneous in the different drug groups. While the
differences are relatively slight and below the mean for
groups such as analgesics (N02) and anti-inflammatories
(M01), there are very wide disparities in other groups such
as bronchodilators (R03), decongestants (R01) and par-
ticularly psychoanaleptics (N06) and psycholeptics
(N05).
Table 3 shows the analysis of active ingredients for which
the active ingredients with the largest difference in utiliza-
tion have been chosen, with a minimum utilization of 1
DID.
Drugs for problems of Attention-disorder hyperactivity
such as methylphenidate show extremely significant dif-
ferences in utilization. In the bronchodilator group, mon-
telukast and terbutaline show differences in utilization
that are higher than the group as a whole (385% and
238% compared to 142% for the R03 group). Within the
antibiotics group, cefuroxime, cefaclor and clarythromi-
Distribution by sex and age of the DID prescriptionFigure 1



















Table 1: Main indicators for prescription-drug utilization in spanish and foreign national children. 
Spaniards Foreign Nationals Difference Sp v. FN p-value
DID 113.67 66.27 72% <0.001
Packages/person 5.55 3.67 51% <0.001
Expense/person € 29.38 € 14.69 100% <0.001
Retail price/person € 41.14 € 21.55 91% <0.001
% co-payment 29% 32% -10% <0.001
Utilization rate 74% 64% 16% <0.001
% DDD generics 20% 18% 11% <0.01
Rates adjusted by age and sex.Page 4 of 9
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tively, compared to 72% for the J01 group.
Within the immigrant population, important differences
are seen in utilization according to the geographical back-
ground and place of birth of the children, as shown in
Table 4.
Certain heterogeneity was detected among immigrants
themselves; children born in their countries of origin uti-
lize fewer prescription drugs than those born in Spain.
Children from western countries, Asia and Latin America
have lower utilization rates than sub-Saharan and North
Africans, although it will be necessary to study their qual-
itative utilization in greater depth in order to understand
this phenomenon.
Discussion
The results presented in this study are quite clear and con-
sistent: prescription drug utilization is much greater in
Spanish children than in immigrant children. In a
National Health Service with universal child cover,
despite what is thought, conveyed [29], and often appears
in different media, our study shows that the utilization of
prescription drugs by the immigrant paediatric popula-
tion is far lower than that of the Spanish population. This
has been demonstrated in the measurement of DID, total
expense and number of packages consumed. Other stud-
ies had demonstrated this low utilization of services,
although not all of them had given in depth study to drug
utilization [5,7,22,30-33]. It has also been shown that this
difference occurred in all therapeutic groups and main
active ingredients although with huge variability.
Table 2: Difference in DID utilization between spaniards and foreign nationals by different anatomical and therapeutic groups.
ATC CLASSIFICATION CATEGORY NAME CODE Difference Sp v. FN p-value
TOTAL DID 72% <0.001
RESPIRATORY SYSTEM R 93% <0.001
ANTI-INFECTIVES FOR SYSTEMIC USE J 65% <0.001
NERVOUS SYSTEM N 146% <0.001
SENSORY ORGANS S 65% <0.001
MUSCULO-SKELETAL SYSTEM M 45% <0.001
HORMONES FOR SYSTEMIC USE EXCL. SEX HORMONES H 104% <0.001
ANTIBACTERIALS FOR SYSTEMIC USE J01 72% <0.001
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03 142% <0.001
COUGH AND COLD PREPARATIONS R05 43% <0.001
ANTI-INFLAMMATORIES AND ANTIRHEUMATICS M01 44% <0.001
OPHTHALMOLOGICALS S01 61% <0.001
NASAL PREPARATIONS R01 146% <0.001
ANTIHISTAMINES FOR SYSTEMIC USE R06 113% <0.001
CORTICOSTEROIDS FOR SYSTEMIC USE H02 112% <0.001
PSYCHOANALEPTICS N06 668% <0.001
ANTICONVULSANTS N03 53% <0.01
ANALGAESICS N02 24% <0.001
PSYCHOLEPTICS N05 109% <0.001
Rates adjusted by age and sex.
Table 3: Main active ingredients with highest DID and largest differences in utilization between spaniards and foreign nationals. 
ATC ACTIVE INGREDIENT DID FN DID SP DIFF. DID P-VALUE
N06BA04 METHYLPHENIDATE 0.50 3.93 687% < 0.001
R03DC03 MONTELUKAST 0.47 2.28 385% < 0.001
R03AC03 TERBUTALINE 0.59 1.98 238% < 0.001
R01AD05 BUDESONIDE (NASAL) 1.45 3.79 162% < 0.001
R01AD09 MOMETASONE 0.55 1.40 157% < 0.001
J01DC02 CEFUROXIME 0.48 1.18 147% < 0.001
H02AB07 PREDNISONE 0.61 1.51 147% < 0.001
J01DC04 CEFACLOR 0.44 1.05 138% < 0.001
R03BA02 BUDESONIDE (INHALATION) 0.98 2.33 138% < 0.001
J01FA09 CLARYTHROMICINE 0.52 1.22 134% < 0.001
R03BB01 IPRATROPIUM BROMIDE 0.57 1.23 117% < 0.001
R05CB01 ACETYLCYSTEINE 1.91 4.14 117% < 0.001
Rates adjusted by age and sex.Page 5 of 9
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in distribution of resources, health system management,
immigration population frequency, and social and demo-
graphic characteristics, our data may be generalizable for
the entire country.
If we assume that the immigrant population has a socio-
economic level that is lower than the Spanish population,
it would seem that immigrants should have lower levels of
health [34-36]. The low drug utilization found in our
study could respond to the classic "Inverse Care Law"
described by Hart in 1971 (patients receive medical care
in inverse proportion to their need) or to their level of
health being higher than expected, or to a combination of
both [37]. There are a number of hypotheses explaining
such striking differences.
One example is accessibility. There may be lower access
for immigrant children, meaning they go to the doctor less
regularly. However, there is no legal reason for this
because the law guarantees their right to be attended in
equal conditions. The Rivera Study concluded that there
were no significant problems of access in Spain [7], but
other authors have concluded that there are different bar-
riers of culture, language, legal status, lack of familiarity
with the health care system, and others that are related to
work and timetables [38].
In order to explain this further, it would be of great use to
have information on the utilization of the different health
services by these patients. Data on frequency of consulta-
tions are disputed and new studies would be necessary to
prove this point, but it would seem that immigrants make
fewer consultations than Spaniards [5,7,11,32,33,39,40].
This factor would justify the lower overall prescription
drug utilization, but not the important differences existing
in the utilization profile.
This study only evaluates drugs prescribed by the public
health services and does not include those dispensed with
private medical prescriptions or those acquired over the
counter without prescription, a situation that is quite
common in paediatrics. It is estimated that of the total
Spanish pharmaceutical market handled through the
Pharmacy Service in 2006, 75.4% corresponded to the
Spaninh National Health Service [41]. If this private utili-
zation were taken into account, it would widen even fur-
ther the differences between the two population groups,
given that it is likely that immigrants would make less use
of these services.
The cost of co-payment in Spain is very low and we do not
consider this to be a reason that justifies the differences. In
the analysis of utilization shown in Table 3, it could be
suspected that the part to be paid by patients for some
active ingredients influences patients with lower purchas-
ing power to not accept having to pay a higher proportion
of the price of a drug, therefore dissuading the doctor to
prescribe it.
However, methylphenidate, the most utilized brand, has
an extremely low price to be paid by patients, and both
montelukast and terbutaline have a reduced co-payment
scale - 10% of the total - with a maximum of €2.64 per
package. In the case of the antibiotics cefuroxime, cefaclor
and clarythromicine, the part to be paid by the patient is
higher than for most drugs routinely prescribed in paedi-
atrics such as amoxicillin and amoxicillin with clavulanic
acid, with a lower cost per treatment, although these are
acute treatments with a total cost that can never be high.
Other factors may also be present in their being pre-
scribed.
There are numerous studies pointing out that immigrants
usually have a better level of health than their host pop-
ulations because the healthiest are more likely to migrate
("healthy migration effect") and this population group
has better lifestyles. These studies have been made on gen-
eral populations and it is doubtful whether they can be
applied to the paediatric population that has not under-
gone the selection process involved in emigrating to
another country [5,7,39,42-47].
Some cultural and sociological issues arise when we ana-
lyse the enormous differences in the utilization of bron-
Table 4: Differences in DID prescription-drug utilization by place of birth of foreign national children. Aragón 2006.
GEOGRAPHICAL BACKGROUND DID FN DID SP DIFF. DID P-VALUE
FOREIGN NATIONAL BORN IN SPAIN 85.92 113.67 32% <0.001
SUB-SAHARAN AFRICA 71.97 113.67 58% <0.001
NORTH AFRICA 64.52 113.67 76% <0.001
EASTERN EUROPE 56.50 113.67 101% <0.001
LATIN AMERICA 55.13 113.67 106% <0.001
ASIA 49.70 113.67 129% <0.001
WESTERN EUROPE AND NORTH AMERICA 48.08 113.67 136% <0.001
Rates adjusted by age and sex.Page 6 of 9
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(Table 3): Should we be considering that there is lower
incidence of Asthma or Hyperactivity disorders in the
immigrant population? Are we confirming the hygienist
theories regarding the origin of asthma? Do immigrants
with these conditions not receive treatment? Are Spanish
children being overdiagnosed or overtreated for these
conditions? Are these drugs being put to the correct use for
which they were approved? Why do Spanish children uti-
lize the latest Asthma treatments?
Prescription drug utilization does not only obey factors of
health or illness. There are important sociological factors
that influence it. The concept of and attitudes toward
health and illness may be different in both groups. Our
society is medicalized and seeks the solution to many of
its problems in drugs. Different studies have confirmed
that the self perception of good health is higher among
immigrants than among locals [5,7,42].
Health care in most of the countries of origin of immi-
grants have shortcomings that often means medical treat-
ment is given those processes considered most pressing,
while people geneally turn to home remedies for different
ailments. Over time, immigrants adapt and are assimi-
lated into the culture of greater health-resource utilization
of the host country, which would justify the differences
found between children of immigrants born in Spain and
those born in their countries of origin.
Likewise, we should also look at the concept of health and
illness held by the immigrant population and the culture
of health-resource utilization in their countries of origin
that might justify a differential pattern of "felt morbidity".
Health and illness are socially-constructed concepts and
they vary in relation to the social and cultural context in
which they are produced.
Taking into account a more biological concept, perhaps
another motive could be health and the scale of needs.
Consultations with immigrants tend to relate to more
acute events; follow up is much more complex once the
event for which the consultation was made has been over-
come. Immigrants are very often unaccustomed to their
children making regular visits to the doctor if they feel
well. Adherence to chronic treatments is difficult. Preven-
tive activities do not form a part of their requirements
because they are not seen to be necessary, at least during
their first years in Spain [48-50].
The finding that the differences are lower between drugs
treating "acute" conditions (analgesics, anti-inflammato-
ries and antibiotics) than drugs treating chronic condi-
tions (Asthma and Hyperactivity) support this hypothesis.
Conclusion
In conclusion, prescription drug utilization is much
greater in Spanish children than in immigrant children,
particularly with reference to bronchodilators (montelu-
kast and terbutaline) and Attention-disorder hyperactivity
drugs such as methylphenidate.
Prescription drug utilization by the immigrant paediatric
population is much lower than for the Spanish popula-
tion. Probably, cultural, sociological and accesibility fac-
tors are the factors that contribute more to these
differences. Other studies will be needed to further ana-
lyse the disparities shown by drug subgroups, the ideal-
ness and suitability of prescription, the background of the
immigrant population and frequency of consultations,
among others, in order to assist us in ascertaining the
causes of this situation.
"WHAT THIS PAPER ADDS"
What is already known about this topic?
There is not enough information about consumption of
health resources from the immigrant paediatric popula-
tion. Population studies could highlight disparities and
explain variability in clinical practice.
What this study adds?
Pharmaceutical consumption from immigrant children in
a public health system such as Spain's, with universal
health care, is very much lower than for native-born chil-
dren. There are many differences, depending on country
of origin and drug type. This fact entails relevant implica-
tions for the health planning and opens new research
lines.
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